Zenas BioPharma (NASDAQ:ZBIO) Given Buy Rating at HC Wainwright

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Marketbeat reports. They currently have a $44.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 63.14% from the company’s current price.

ZBIO has been the subject of a number of other research reports. Guggenheim reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Zenas BioPharma in a research note on Friday, August 14th. Weiss Ratings lowered shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Wedbush reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research note on Friday, August 14th. Morgan Stanley lifted their target price on shares of Zenas BioPharma from $22.00 to $32.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Finally, Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $46.71.

Zenas BioPharma Price Performance

Zenas BioPharma stock traded up $0.21 during mid-day trading on Wednesday, hitting $26.97. The company’s stock had a trading volume of 623,232 shares, compared to its average volume of 818,694. The company has a quick ratio of 9.93, a current ratio of 9.93 and a debt-to-equity ratio of 1.57. The stock has a market capitalization of $1.76 billion, a P/E ratio of -3.00 and a beta of -1.04. Zenas BioPharma has a twelve month low of $13.50 and a twelve month high of $44.60. The stock’s fifty day moving average price is $31.47 and its two-hundred day moving average price is $25.08.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The business had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $15.00 million. Research analysts forecast that Zenas BioPharma will post -5.81 earnings per share for the current year.

Institutional Investors Weigh In On Zenas BioPharma

Several institutional investors and hedge funds have recently modified their holdings of ZBIO. Quantbot Technologies LP acquired a new stake in shares of Zenas BioPharma in the 2nd quarter valued at $49,000. Jupiter Topco LLC acquired a new stake in shares of Zenas BioPharma in the 2nd quarter valued at $201,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Zenas BioPharma in the 2nd quarter valued at $204,000. ProShare Advisors LLC acquired a new stake in shares of Zenas BioPharma in the 4th quarter valued at $211,000. Finally, Sei Investments Co. acquired a new stake in shares of Zenas BioPharma in the 1st quarter valued at $242,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.

Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus.